CervoMed (CRVO) said Wednesday it has received orphan drug designation for its investigational drug neflamapimod from the US Food and Drug Administration to treat frontotemporal dementia.
Neflamapimod was "generally well tolerated" in phase 1 and phase 2 clinical studies, the company said, adding that it intends to start a phase 3 trial in dementia with Lewy bodies in mid-2025.
Shares of CervoMed rose 15% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.